Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vepdegestrant (ARV-471) in Japanese Patients with ER+/HER2- Advanced Breast Cancer
NCT05463952Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2022
- Primary completion
- May 2023
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vepdegestrant in breast cancer, sponsored by Pfizer. Primary endpoint: Dose Limiting Toxicity. Started Aug 2022; status: active, not recruiting.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05463952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463952.